Efficacy of an XPO1 inhibitor in combination with irinotecan in a preclinical colorectal cancer model

BackgroundIrinotecan is a topoisomerase I inhibitor that is commonly used as a chemotherapeutic regimen for the treatment of metastatic colorectal cancer (CRC) by producing cytotoxic DNA damage. However, drug resistance frequently occurs, underscoring the importance of developing newer treatment str...

Descripción completa

Detalles Bibliográficos

Autores principales:	Robert W. Lentz, Adrian T. A. Dominguez, Nicole Baranda Balmaceda, John J. Arcaroli, Stacey M. Bagby, Cameron A. Binns, Stephen G. Smoots, Marilyn M. Jackson, Morgan Macbeth, Tessa Holmstoen, Tapahsama Banerjee, Phaedra A. Whitty, S. Stephen Yi, Christopher H. Lieu, Wells A. Messersmith, Todd M. Pitts
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Frontiers Media S.A. 2026-03-01
Colección:	Frontiers in Oncology
Materias:	chemotherapy colorectal cancer eltanexor selinexor XPO1
Acceso en línea:	https://www.frontiersin.org/articles/10.3389/fonc.2026.1721685/full
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!